FENC at a glance
FENNEC PHARMACEUTICALS INC. (FENC, SEC CIK 1211583) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 17, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), FENNEC PHARMACEUTICALS INC. (FENC) reported revenue of $44.6 million (down 6.1% from FY2024) and a net loss of $9.7 million. Diluted EPS was -$0.34.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding FENNEC PHARMACEUTICALS INC. (FENC) shares worth $44.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Brughera Marco Maria on September 15, 2026 of 15,545 shares at $10.29 per share.
- In the last 90 days, FENC insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $44.6M
- −6.1% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$1.4M
- 13F holders
- 21 funds
- $44.9M · +3 vs prior quarter
- Latest 8-K
- Sep 17, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $17.874M vs $9.652M YoY, up $8.222M
- Operating margin 9.7% vs (28.3%) YoY, with operating income $1.737M vs loss $2.732M
- PEDMARK sales $17.164M vs $9.652M, while other revenue contributed $710K
- Cash $41.249M vs $36.788M at December 31, 2025, up $4.461M
- Six-month operating cash flow $2.429M vs $(8.004)M, with financing cash flow $2.032M, including option exercises
Risk Factors
- No Risk Factors section provided in the excerpt
- No newly added, updated, regulatory, operational, competitive, or financial risks identifiable
- Insider trading arrangements: CFO disposition plan covers up to 75,000 shares through September 30, 2026
- Director disposition plan covers up to 55,545 shares through June 25, 2027
AI summary of the FENC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Phase 2 STS-J01 study in Japan met its primary endpoint for PEDMARK®
- Significant hearing protection demonstrated in cisplatin-treated patients
Item EX-99.1: Item EX-99.1
- Phase 2 STS-J01 met its primary endpoint, with ASHA-defined hearing loss at 24.0% versus 56.4% historical benchmark
- 95.8% objective tumor response rate supports six-hour PEDMARK administration without apparent cisplatin antitumor interference
Item 5.07: Submission of Matters to a Vote of Security Holders
- All five director nominees re-elected, preserving board continuity through the next annual meeting
- Haskell & White LLP appointment approved with 26,091,716 votes, confirming auditor oversight
Item 8.01: Other Events
- New PEDMARK research to be presented at ASCO 2026
- Data spans multiple patient populations and tumor types
AI summaries of FENC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FENC
Don't miss the next FENC filing
- Alerts as it files. A push when FENC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FENC, by share count.
- Ask anything. An AI agent that reads every FENC filing and answers with sources.
FENC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cioffi Christiana Marie | A | Sep 30, 2026 | 156 | - |
| Andrade Robert | A | Sep 30, 2026 | 1,703 | - |
| Evans Terry L | A | Sep 30, 2026 | 168 | - |
| Sayad Pierre Sargis | A | Sep 30, 2026 | 168 | - |
| Hackman Jeffrey S. | A | Sep 30, 2026 | 1,159 | - |
| Brughera Marco Maria | M | Sep 15, 2026 | 15,545 | $2.11 |
| Brughera Marco Maria | Sell | Sep 15, 2026 | 15,545 | $10.29 |
| Brughera Marco Maria | M | Sep 15, 2026 | 15,545 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $21.3M | $47.5M | $44.6M |
| Gross Profit | $20.0M | - | - |
| Operating Income | -$12.8M | $2.6M | -$6.3M |
| Net Income | - | -$436K | -$9.7M |
| Gross Margin | 94.1% | - | - |
| Op. Margin | -60.1% | 5.4% | -14.1% |
| Net Margin | - | -0.9% | -21.8% |
| Balance Sheet | |||
| Total Assets | $26.9M | $44.9M | $70.6M |
| Equity | - | -$5.9M | $35.5M |
| ROE | - | 7.4% | -27.5% |
| Per Share | |||
| EPS | $-0.60 | $-0.02 | $-0.34 |
| Cash Flow | |||
| Operating CF | -$17.1M | $27.0M | -$12.5M |
Source: XBRL data in FENNEC PHARMACEUTICALS INC. (FENC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate FENC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $44.9M |
| Q1 2026 | 18 | $21.7M |
| Q4 2025 | 19 | $26.6M |
| Q3 2025 | 21 | $29.9M |
| Q2 2025 | 20 | $26.2M |
| Q1 2025 | 13 | $11.6M |
| Q4 2024 | 8 | $9.7M |
| Q3 2024 | 6 | $2.8M |
- BlackRock+358.9K (+26%)
- AQR Capital Management+68.7K (+285%)
- State Street Corp+66.9K (+19%)
- Vanguard Portfolio Management LLC+31.5K (+19%)
- Northern Trust+15.8K (+10%)
- Citadel Advisors LLC−82.6K (-54%)
- Vanguard Capital Management LLC−57.8K (-6%)
- Goldman Sachs Group−22.2K (-40%)
- Bank of America Corp−6.5K (-24%)
- Renaissance Technologies LLC+134.2K
- Two Sigma Investments+60.3K
- Millennium Management+26.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 126 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FENC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
FENC SEC filings: frequently asked questions
Are FENC insiders buying or selling?
In the last 90 days, FENNEC PHARMACEUTICALS INC. (FENC) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold FENC stock?
As of June 30, 2026, the largest FENNEC PHARMACEUTICALS INC. (FENC) holders among the 13F filers tracked by SignalX were BlackRock ($18.6 million), Vanguard Capital Management LLC ($9.0 million), State Street Corp ($4.6 million), Morgan Stanley ($2.4 million), Vanguard Portfolio Management LLC ($2.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FENC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), FENNEC PHARMACEUTICALS INC. (FENC) reported revenue of $44.6 million (down 6.1% from FY2024) and a net loss of $9.7 million. Diluted EPS was -$0.34. The figures come from the XBRL data in the 10-K.
What did FENC report in its latest 8-K?
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K on September 17, 2026 reporting Item 8.01 (Other Events). Phase 2 STS-J01 study in Japan met its primary endpoint for PEDMARK®.
What are the latest FENC SEC filings?
FENNEC PHARMACEUTICALS INC. (FENC) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 17, 2026 and a Form 4 insider filing on October 1, 2026.
What is FENC's SEC CIK number?
FENNEC PHARMACEUTICALS INC. (FENC)'s SEC Central Index Key (CIK) is 1211583. EDGAR lists every FENC filing under that number.
Ask anything about FENC
The research agent reads FENC's filings, financials, insider trades and 13F holders, then answers with sources.